Reference

Indolinone derivatives as kinase inhibitors and their preparation, pharmaceutical compositions, and use in the treatment of proliferative diseases

All Rights Reserved.Some chemicals with cas registry numbers like 16153-81-4 and 919103-48-3 are also used. Indolinone derivatives as kinase inhibitors and their preparation, pharmaceutical compositions, and use in the treatment of proliferative diseases. Wurster, Julie A.; Yee, Richard C. (Allergan, Inc., USA). PCT Int. Appl. WO 2007008985 A2 18 Jan 2007, 26pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2. APPLICATION: WO 2006-US27052 11 Jul 2006. PRIORITY: US 2005-699065P 13 Jul 2005. DOCUMENT TYPE: Patent CA Section: 27 (Heterocyclic Compounds (One Hetero Atom)) Section cross-reference(s): 1, 63 The invention relates to org. mols. of formula I and II capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. Compds. of formula I and II wherein X is CO, CS, (un)substituted CH2, O, S, NH and derivs.; Z is C1-8 alkyl, Ph, CH2OH; Ac, CH2CH2OH, CH2CH2CH2OH, etc.; R1 is H and Me; R3 is H, C1-8 alkyl, Ph, CH2OH, AC, CH2CH2OH, etc.; A is (un)substituted phenyl; B is H, OH, C1-8 alkyl, aryl, (un)substituted CH2, etc.; the wavy bond is E and Z geometry; and their pharmaceutically acceptable salts thereof are claimed. Example compd. III was prepd. by amination of 3-(3-hydroxymethylene-2-oxo-2,3-dihydro-1H-indol-6-ylsulfanyl)-N-meth ylbenzamide with 4-(4-methylpiperazin-1-yl)aniline. All the invention compds. were evaluated for their kinase inhibitory activity. The present invention relates to org. mols. of following formulas I and II capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. .